Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/87875
Title:
Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer.
Authors:
Robertson, John F R; Howell, Anthony ( 0000-0002-3879-5991 ) ; Buzdar, Aman; Von Euler, M; Lee, D
Abstract:
BACKGROUND: This paper reports on the clinical relevance of durable static disease (SD) (> or = 24 weeks) in breast cancer patients treated with the aromatase inhibitor anastrozole. PATIENTS AND METHODS: All patients were part of two prospective, randomised, multicentre studies in postmenopausal women with advanced disease in which megestrol acetate was compared with anastrozole 1 mg. Survival from initiation of treatment was analysed by the response type, i.e., complete response (CR)/partial response (PR), static disease (SD) (> or = 24 weeks), or progressive disease (PD), achieved on therapy. RESULTS: Median survival with anastrozole 1 mg was similar between patients who obtained CR/PR and SD (> or = 24 weeks). Similarly, no difference in survival was observed in patients treated with megestrol acetate who achieved CR/PR and SD. With both treatments patients with CR/PR and SD had improved survival over those patients with PD within 24 weeks. There was no difference between treatment arms for patients showing PD within 24 weeks. CONCLUSIONS: These data confirm that durable SD (> or = 24 weeks) is a clinically useful remission criterion in postmenopausal women with advanced breast cancer with predictive value for overall survival. It also confirms the value of this endpoint with anastrozole, a new generation aromatase inhibitor.
Affiliation:
Department of Surgery, City Hospital, Nottingham, UK. John.Robertson@nottingham.ac.uk
Citation:
Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. 1999, 58 (2):157-62 Breast Cancer Res. Treat.
Journal:
Breast Cancer Research and Treatment
Issue Date:
Nov-1999
URI:
http://hdl.handle.net/10541/87875
DOI:
10.1023/A:1006391902868
PubMed ID:
10674881
Type:
Article
Language:
en
ISSN:
0167-6806
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRobertson, John F Ren
dc.contributor.authorHowell, Anthonyen
dc.contributor.authorBuzdar, Amanen
dc.contributor.authorVon Euler, Men
dc.contributor.authorLee, Den
dc.date.accessioned2009-12-14T13:24:41Z-
dc.date.available2009-12-14T13:24:41Z-
dc.date.issued1999-11-
dc.identifier.citationStatic disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. 1999, 58 (2):157-62 Breast Cancer Res. Treat.en
dc.identifier.issn0167-6806-
dc.identifier.pmid10674881-
dc.identifier.doi10.1023/A:1006391902868-
dc.identifier.urihttp://hdl.handle.net/10541/87875-
dc.description.abstractBACKGROUND: This paper reports on the clinical relevance of durable static disease (SD) (> or = 24 weeks) in breast cancer patients treated with the aromatase inhibitor anastrozole. PATIENTS AND METHODS: All patients were part of two prospective, randomised, multicentre studies in postmenopausal women with advanced disease in which megestrol acetate was compared with anastrozole 1 mg. Survival from initiation of treatment was analysed by the response type, i.e., complete response (CR)/partial response (PR), static disease (SD) (> or = 24 weeks), or progressive disease (PD), achieved on therapy. RESULTS: Median survival with anastrozole 1 mg was similar between patients who obtained CR/PR and SD (> or = 24 weeks). Similarly, no difference in survival was observed in patients treated with megestrol acetate who achieved CR/PR and SD. With both treatments patients with CR/PR and SD had improved survival over those patients with PD within 24 weeks. There was no difference between treatment arms for patients showing PD within 24 weeks. CONCLUSIONS: These data confirm that durable SD (> or = 24 weeks) is a clinically useful remission criterion in postmenopausal women with advanced breast cancer with predictive value for overall survival. It also confirms the value of this endpoint with anastrozole, a new generation aromatase inhibitor.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAntineoplastic Agents, Hormonal-
dc.subject.meshAromatase Inhibitors-
dc.subject.meshBreast Neoplasms-
dc.subject.meshDose-Response Relationship, Drug-
dc.subject.meshDouble-Blind Method-
dc.subject.meshEnzyme Inhibitors-
dc.subject.meshEurope-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMegestrol Acetate-
dc.subject.meshNitriles-
dc.subject.meshPostmenopause-
dc.subject.meshProspective Studies-
dc.subject.meshSurvival Analysis-
dc.subject.meshTriazoles-
dc.subject.meshUnited States-
dc.titleStatic disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Surgery, City Hospital, Nottingham, UK. John.Robertson@nottingham.ac.uken
dc.identifier.journalBreast Cancer Research and Treatmenten

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.